Patient Gateway

RSS Feed

EGFR, ALK, KRAS: Your Lung Cancer Biomarker Questions Answered

Neurotoxicity associated with ALK inhibitors in the treatment of non-small cell lung cancer: an analysis of the FAERS database

Lorlatinib-associated sensorineural deafness in a non-small cell lung cancer patient with ALK-fusion: a Case Report

ASCO 2026.3.4 Living Guideline: Lorlatinib Takes Priority in First-Line ALK-Positive NSCLC After Landmark Seven-Year CROWN Results

ASCO 2026.3.4 Living Guideline: Lorlatinib Takes Priority in First-Line ALK-Positive NSCLC After Landmark Seven-Year CROWN Results

Landscape and clinical impact of heterogeneous ALK resistance mutations detected by comprehensive genomic profiling in patients with NSCLC

Computational characterization of Paraphamide B as a potential EGFR-preferential dual EGFR/ALK-binding candidate for non-small cell lung cancer

International Clinical Trial: First-line treatment preferences for ALK-positive non-small cell lung cancer

University Hospital Puerta de Hierro Majadahonda Describes Findings in Obesity, Fitness and Wellness (Real-world evolution of first-line ALK-positive NSCLC management in Spain)

Targeted Drug ALK Inhibitors for NSCLC Market Size & CAGR 2033

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.